Search

Your search keyword '"Cereja, Sophie"' showing total 18 results

Search Constraints

Start Over You searched for: Author "Cereja, Sophie" Remove constraint Author: "Cereja, Sophie"
18 results on '"Cereja, Sophie"'

Search Results

2. Carfilzomib maintenance in newly diagnosed non-transplant eligible multiple myeloma

3. P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN

5. Evolving Characteristics and Outcome of Secondary Acute Promyelocytic Leukemia (APL): A Prospective Analysis by the French-Belgian-Swiss APL Group

6. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

7. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.

8. Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial

9. Light Chain Escape in Multiple Myeloma

10. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03) / 57th Annual Meeting of the American-Society-of-Hematology - Orlando, FL

11. Carfilzomib Weekly Plus Melphalan and Prednisone in Newly Diagnosed Elderly Multiple Myeloma (IFM 2012-03)

12. IFM2012-03

13. Long-Term Outcome of Lower-Risk MDS Patients after Immunosuppressive Therapy (IST) with Anti-Thymocyte Globulin (ATG)+/- Cyclosporin A (CsA)

14. Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases

15. Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?

16. Rituximab, Fludarabine and Alkylating Agents in Peripheral Neuropathies Related to IgM Monoclonal Gammopathy with Autoantibody Activity against Myelin-Associated-Glycoprotein : a Retrospective Study of 15 Patients.

17. Combination of Bortezomib and Dexamethasone (VD) or Bortezomib, Adriamycine and Dexamethasone (PAD) Followed by High Dose Therapy and Peripheral Blood Stem Cell Transplantation in First-Line Treatment of T(4;14) Multiple Myeloma : a Prospective Study of the MAG Group.

18. Posterior reversible encephalopathy syndrome (PRES) and myeloma.

Catalog

Books, media, physical & digital resources